Ledipasvir - CAS# 1256388-51-8 0153 Effect of DNA damage response

Effect of DNA damage response by quinazolinone analogue HMJ-38 on human umbilical vein endothelial cells: Evidence for γH2A

(1997) Nature

SKLB-610 inhibited angiogenesis-related tyrosine kinase VEGFR2

10 mM SB431542

5-3(6)1-2-4(7)8/h2-9

Ledipasvir - CAS# 1256388-51-8 0153 Effect of DNA damage responseLedipasvir, also known as GS 5885, CAS No. 1256388 51 8, is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg sofosbuvir 400 mg (trade name Harvoni). The ledipasvir sofosbuvir combination is a direct acting antiviral agent that interferes with HCV replication and can be used to treat